- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00895141
Effect of Saturated Fat on Large Low-density Lipoprotein (LDL) and High-density Lipoprotein (HDL)
January 10, 2013 updated by: UCSF Benioff Children's Hospital Oakland
Changes in LDL and HDL With Increased Intake of Saturated Fat From Dairy Foods in Individuals With Atherogenic Dyslipidemia and LDL Subclass Pattern B
The purpose of the study is to test whether increased saturated fat intake results in increased levels of larger LDL and HDL particles in individuals with LDL Pattern B.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Increased saturated fat intake is known to elevate plasma levels of both low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C), however, less is know regarding the effect of saturated fat on lipoprotein subclasses.
We previously showed that, in the context of a reduced carbohydrate diet, saturated fat induced increases in LDL cholesterol were apparently due to increases in large, more buoyant LDL without increases in small, dense LDL.
This finding was supported by a previous dietary intervention study showing a correlation between saturated fat intake and large LDL.
In both cases, this increase in large LDL was correlated with an increase in large HDL.
In this study, we will test the following specific hypotheses regarding changes in plasma lipoproteins induced by a diet high in myristic acid and other saturated fats derived primarily from dairy sources in individuals with LDL subclass pattern B: 1) there will be a coordinate increase in levels of large HDL particles that are considered anti-atherogenic and large LDL particles that are less strongly associated with increased CVD risk than smaller LDL; 2) this change in lipoprotein profile will result in a higher proportion of pattern B individuals converting to LDL subclass pattern A (predominance of larger LDL); and 3) the coordinate increase in large HDL and LDL is due to a common underlying pathway.
The latter hypothesis will be addressed by assaying cholesterol ester transfer protein (CETP), hepatic lipase (HL), and lipoprotein lipase (LPL).
Study Type
Interventional
Enrollment (Actual)
53
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Berkeley, California, United States, 94705
- Cholesterol Research Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Men or postmenopausal woman between 18-70 yrs
- Body Mass Index between 25-35
- Blood pressure <150/90
- Non smoking
- Agrees to consume no alcohol or dietary supplements during the study
- LDL Subclass Pattern B
- Total cholesterol and LDLC ≤95th percentile for sex and age
- Fasting triglycerides ≤ 500mg/dl
- Fasting blood sugar < 126 mg/dl
- At least 3 months weight stable
Exclusion Criteria:
- History of coronary heart disease, cerebrovascular disease, peripheral vascular disease, bleeding disorder, liver or renal disease, diabetes, lung disease, HIV, or cancer (other than skin) in the last 5 years
- Taking drugs known to affect lipid metabolism or hormones
- Abnormal thyroid stimulating hormone (TSH)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Low saturated fat diet
Moderate carbohydrate (35%E), moderate protein (25%E), high fat (40%E) diet with 8%E saturated fat
|
Moderate carbohydrate (35%E), moderate protein (25%E), high fat diet (40%E) with 8%E saturated fat
Moderate carbohydrate (35%E), moderate protein (25%E), high fat (40%E) diet with 20%E saturated fat
|
Experimental: High saturated fat diet
Moderate carbohydrate (35%E), moderate protein (25%E), high fat (40%E) diet with 20%E saturated fat
|
Moderate carbohydrate (35%E), moderate protein (25%E), high fat diet (40%E) with 8%E saturated fat
Moderate carbohydrate (35%E), moderate protein (25%E), high fat (40%E) diet with 20%E saturated fat
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Large LDL (LDL I + 2a) (mg/dl)
Time Frame: 3 wk, 6 wk
|
3 wk, 6 wk
|
Large HDL (HDL2b) (mg/dl)
Time Frame: 3 wk, 6 wk
|
3 wk, 6 wk
|
LDL peak particle size
Time Frame: 3 wk, 6 wk
|
3 wk, 6 wk
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Triglycerides (mg/dl)
Time Frame: 3 wk, 6 wk
|
3 wk, 6 wk
|
Total Cholesterol (mg/dl)
Time Frame: 3 wk, 6 wk
|
3 wk, 6 wk
|
LDL cholesterol (mg/dl)
Time Frame: 3 wk, 6 wk
|
3 wk, 6 wk
|
HDL cholesterol (mg/dl)
Time Frame: 3 wk, 6 wk
|
3 wk, 6 wk
|
Apolipoprotein AI (mg/dl)
Time Frame: 3 wk, 6 wk
|
3 wk, 6 wk
|
Apolipoprotein B (mg/dl)
Time Frame: 3 wk, 6 wk
|
3 wk, 6 wk
|
Medium LDL (LDL2b) (mg/dl)
Time Frame: 3 wk, 6 wk
|
3 wk, 6 wk
|
Small LDL (LDL3a) (mg/dl)
Time Frame: 3 wk, 6 wk
|
3 wk, 6 wk
|
Hepatic Lipase Activity
Time Frame: 3 wk, 6 wk
|
3 wk, 6 wk
|
Lipoprotein Lipase Activity
Time Frame: 3 wk, 6 wk
|
3 wk, 6 wk
|
Cholesteryl Ester Transfer Protein Activity
Time Frame: 3 wk, 6 wk
|
3 wk, 6 wk
|
Very Small LDL (LDL3b, 4a, 4b) (mg/dl)
Time Frame: 3 wk, 6 wk
|
3 wk, 6 wk
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2009
Primary Completion (Actual)
September 1, 2010
Study Completion (Actual)
April 1, 2011
Study Registration Dates
First Submitted
May 7, 2009
First Submitted That Met QC Criteria
May 7, 2009
First Posted (Estimate)
May 8, 2009
Study Record Updates
Last Update Posted (Estimate)
January 14, 2013
Last Update Submitted That Met QC Criteria
January 10, 2013
Last Verified
January 1, 2013
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MM3355
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dyslipidemia
-
Kowa Research Institute, Inc.CompletedMixed Dyslipidemia | Primary DyslipidemiaUnited States
-
Chong Kun Dang PharmaceuticalCompletedDyslipidemia (Fredrickson Type Ⅱa) | Dyslipidemia (Fredrickson Type Ⅱb)Korea, Republic of
-
Hanlim Pharm. Co., Ltd.RecruitingMixed DyslipidemiaKorea, Republic of
-
IlDong Pharmaceutical Co LtdNot yet recruiting
-
Arrowhead PharmaceuticalsCompletedMixed DyslipidemiaUnited States, Australia, Poland, New Zealand, Canada, Hungary
-
Provident Clinical ResearchReliant PharmaceuticalsCompleted
-
Arrowhead PharmaceuticalsActive, not recruitingMixed DyslipidemiaUnited States, Australia, Canada, New Zealand
-
Yooyoung Pharmaceutical Co., Ltd.CompletedCombined DyslipidemiaKorea, Republic of
-
Société des Produits Nestlé (SPN)CompletedPrimary DyslipidemiaChina
-
Provident Clinical ResearchReliant PharmaceuticalsUnknown
Clinical Trials on Saturated Fat Diet
-
UCSF Benioff Children's Hospital OaklandNational Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...CompletedInflammation | Cardiovascular Disease | Insulin Resistance | DyslipidemiaUnited States
-
UCSF Benioff Children's Hospital OaklandNational Cattlemen's Beef AssociationCompletedHealthy | Cardiovascular Disease | Atherogenic DyslipidemiaUnited States
-
University of WashingtonVA Puget Sound Health Care SystemCompleted
-
Christiana Care Health ServicesCompleted
-
Kevin DavyAmerican Diabetes AssociationCompleted
-
University of ReadingWellcome TrustCompletedCardiovascular DiseasesUnited Kingdom
-
University of Massachusetts, WorcesterAmerican Cancer Society, Inc.Completed
-
University of Alabama at BirminghamSmartFoods, Inc.Completed
-
Imperial College LondonTerminatedAtherosclerosisUnited Kingdom
-
University of South AustraliaAmerican Egg BoardCompletedHypercholesterolemia | Hyperlipidemias | Diet, Healthy | Physical InactivityAustralia